PREZISTA (darunavir). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.

Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-96.

Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L et al. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol. 2013;85:8-15.

Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55:1120-2.

Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-8.

Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.

Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.

Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-22.

Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, De La Rosa G et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25:333-40.

Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]

Emtriva (emtricitabin). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.

Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011;66(2):363-70.

Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191(6):825-9.

Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore). 2016;95(19):e3634.

Eaton EF, Tamhane A, Davy-Mendez T, Mathews WC, Moore RD, Saag MS et al. Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure. AIDS. 2018;32(3):347-355.

Firnhaber C, Smeaton LM, Grinsztejn B, Lalloo U, Faesen S, Samaneka W et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials. 2015;16(3):89-99.

Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]

Tybost (cobicistat). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.

Gallant J, Moyle G, Berenguer J, Shalit P, Cao H, Liu YP et al. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial. Curr HIV Res. 2017;15(3):216-224.

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53(5):1937-43.

Viread (tenofovir disoproxil). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

Vemlidy (tenofovir alafenamide). Summary of Product Characteristics. European Medicines Agency (EMA); 2018.

Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51(5):496-505.

Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P et al. Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med. 2012;13(7):406-15.

Chawana TD, Reid A, Bwakura T, Gavi S, Nhachi CF. Factors influencing treatment failure in HIV positive adult patients on first line antiretroviral therapy. Cent Afr J Med. 2014;60(5):29-36.

Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG et al. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17(1):438.

Vinikoor MJ, Sinkala E, Chilengi R, Mulenga LB, Chi BH, Zyambo Z et al. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clin Infect Dis. 2017;64(10):1343-1349.

Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800-6.

Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V et al. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. HIV Med. 2011;12(1):4-13.

Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. Renal impairment in patients receiving a tenofovir-cART regimen: Impact of tenofovir trough concentration. J Acquir Immune Defic Syndr 2012 Nov 28;

Pinto Neto LF, Bassetti BR, Fraga IH, Oliveira Santos CR, Ximenes PD, Miranda AE. Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinic. Braz J Infect Dis. 2016;20(1):14-8.

Lim Y, Lyall H, Foster C. Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study. Clin Drug Investig. 2015;35(5):327-33.

Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701.

Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther. 2006;11(2):179-86.

Svedhem-Johansson V, Pugliese P, Brockmeyer NH, Thalme A, Michalik C, Esser S et al. Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV. Curr HIV Res. 2013;11(4):333-41.

Klassen K, Martineau AR, Wilkinson RJ, Cooke G, Courtney AP, Hickson M. The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS One. 2012;7(9):e44845.

Koethe JR, Jenkins CA, Petucci C, Culver J, Shepherd BE, Sterling TR. Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. Medicine (Baltimore). 2016;95(19):e3634.

Triantos C, Kalafateli M, Aggeletopoulou I, Mandellou M, Assimakopoulos S, Tselekouni P et al. Lactate serum concentrations during treatment with nucleos(t)ide analogues in hepatitis B with or without cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(9):998-1003.

Bandeira ACPCS, Elias DBD, Cavalcante MG, Lima DGL, Távora LGF. Antiretroviral changes during the first year of therapy. Rev Assoc Med Bras (1992). 2017;63(7):606-612.

Ombeni W, Kamuhabwa AR. Lipid Profile in HIV-Infected Patients Using First-Line Antiretroviral Drugs. J Int Assoc Provid AIDS Care. 2015;15(2):164-71.

Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-07-24.]